Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Annamycin and PD-1 Blockade Extend Survival in Pancreatic Cancer Models
Moleculin Biotech reports that Annamycin combined with PD-1 blockade increased survival and T-cell infiltration in preclinical pancreatic cancer models.
Mogrify Presents Preclinical Results for Retinal Reprogramming Therapy
Mogrify reports preclinical preservation and restoration of visual function with AAV-delivered transcription factors in a retinal degeneration model.
Rainwater Foundation Awards Over $1M for Tau-Focused Preclinical Research
Rainwater Charitable Foundation awards over $1 million to three researchers advancing preclinical tau-targeted candidates for neurodegenerative diseases.
FDA Approves J&J Rybrevant Faspro for Advanced Head and Neck Cancer in US
FDA grants accelerated approval to Rybrevant Faspro for certain adults with recurrent or metastatic head and neck cancer after prior therapies.
Eccogene to Present ECC1542 Preclinical Obesity Data at ObesityWeek 2026
Eccogene will present preclinical data for ECC1542, an oral small-molecule amylin and calcitonin receptor agonist, at ObesityWeek 2026 in Maryland.
Novartis Pelacarsen Lowers Lp(a) 78% but Fails to Cut Cardiovascular Events
Novartis’ pelacarsen lowered Lp(a) by 78% in a large outcomes trial but failed to reduce cardiovascular events, raising questions for other Lp(a) therapies.
India Cuts Prices for 1,364 Anti-Cancer Formulations, Saving Consumers
India has revised maximum retail prices for 1,364 anti-cancer formulations, with 679 brands cut by over 50% and projected annual savings of ₹3,540.38 crore.
Teva and Samsung Bioepis Expand US Biosimilar Deal for Eticovo, Infliximab
Teva and Samsung Bioepis signed a US deal covering two FDA-approved immunology biosimilars, with infliximab rights set to transfer in Q3 2027.
FDA Clears PANDA Phase 3 Plan for Pentixapharm’s PentixaFor PET/CT Study
The FDA raised no concerns over Pentixapharm’s Phase 3 PANDA protocol for [68Ga]Ga-PentixaFor PET/CT, with enrollment planned for the first quarter of 2027.
SK Biopharmaceuticals Files FDA Application for Cenobamate in Epilepsy
SK Biopharmaceuticals filed an FDA application for cenobamate in generalized tonic-clonic seizures after Phase 3 results showed a 71.9% median reduction.
AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals in China
AbbVie and Brise Pharmaceuticals disclosed a deal worth up to $757m for two preclinical migraine programmes, with Brise leading discovery activities.
Link Biologics Completes Preclinical Tests for LB001 Dry Eye Drug Therapy
Link Biologics completed IND-enabling preclinical studies for LB001 dry eye drops, reporting favourable tolerability and targeting an IND filing in Q1 2027.
1
2
3
4
5
6